Evidence map›Paper›PMID 34252946›Full record

ArticleBioinformatics (Oxford, England)2021

Optimizing blood-brain barrier permeation through deep reinforcement learning for de novo drug design.

Tiago Pereira, Maryam Abbasi, José Luis Oliveira, Bernardete Ribeiro, Joel Arrais

Open access · hybridAbstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Peptide-functionalized nanoparticles for brain-targeted therapeutics.Drug delivery and translational research · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Tiago PereiraCSUC/DEI, University of Coimbra, Coimbra 3030-290, Portugal.
Maryam AbbasiCSUC/DEI, University of Coimbra, Coimbra 3030-290, Portugal.
José Luis OliveiraIEETA/DETI, University of Aveiro, Aveiro 3810-193, Portugal.
Bernardete RibeiroCSUC/DEI, University of Coimbra, Coimbra 3030-290, Portugal.
Joel ArraisCSUC/DEI, University of Coimbra, Coimbra 3030-290, Portugal.
University of Coimbra · PTUniversity of Aveiro · PT

Funding

D4 - Deep Drug Discovery and Deployment CENTRO-01-0145-FEDER-029266Portuguese Research Agency FCT
6 · The paper itself

Abstract

motivationThe process of placing new drugs into the market is time-consuming, expensive and complex. The application of computational methods for designing molecules with bespoke properties can contribute to saving resources throughout this process. However, the fundamental properties to be optimized are often not considered or conflicting with each other. In this work, we propose a novel approach to consider both the biological property and the bioavailability of compounds through a deep reinforcement learning framework for the targeted generation of compounds. We aim to obtain a promising set of selective compounds for the adenosine A2A receptor and, simultaneously, that have the necessary properties in terms of solubility and permeability across the blood-brain barrier to reach the site of action. The cornerstone of the framework is based on a recurrent neural network architecture, the Generator. It seeks to learn the building rules of valid molecules to sample new compounds further. Also, two Predictors are trained to estimate the properties of interest of the new molecules. Finally, the fine-tuning of the Generator was performed with reinforcement learning, integrated with multi-objective optimization and exploratory techniques to ensure that the Generator is adequately biased.

resultsThe biased Generator can generate an interesting set of molecules, with approximately 85% having the two fundamental properties biased as desired. Thus, this approach has transformed a general molecule generator into a model focused on optimizing specific objectives. Furthermore, the molecules' synthesizability and drug-likeness demonstrate the potential applicability of the de novo drug design in medicinal chemistry. AVAILABILITY AND IMPLEMENTATION: All code is publicly available in the https://github.com/larngroup/De-Novo-Drug-Design. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

Indexed as

Blood-Brain BarrierDrug DesignBiological TransportNeural Networks, Computer

Identifiers

PMID34252946
PMCPMC8336597
OpenAlexW3179318616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.